First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ALN-SOD in Participants With Amyotrophic Lateral Sclerosis and SOD1 Mutations
Latest Information Update: 05 Jun 2025
At a glance
- Drugs ALN SOD (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; First in man
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.
- 15 Aug 2024 Planned End Date changed from 28 Apr 2029 to 26 Apr 2029.
- 15 Aug 2024 Planned primary completion date changed from 28 Apr 2029 to 26 Apr 2029.